Stock Information

• B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125
  Tue, Jun 30, 2026 10:56 AM
• Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $136
  Mon, Jun 29, 2026 11:08 AM
• B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $155
  Mon, Jun 29, 2026 10:35 AM
• Canaccord Genuity Maintains Buy on Kymera Therapeutics, Raises Price Target to $129
  Fri, Jun 26, 2026 11:06 AM
• These stocks are gapping in today's session
  Thu, Jun 25, 2026 2:30 PM
• Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
  Thu, Jun 25, 2026 1:19 PM
• BTIG Reiterates Buy on Kymera Therapeutics, Maintains $134 Price Target
  Thu, Jun 25, 2026 12:20 PM
• Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High
  Thu, Jun 25, 2026 12:18 PM
• Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday
  Thu, Jun 25, 2026 9:55 AM
• Kymera Therapeutics Completes Enrollment In Global BROADEN2 Phase 2b Trial Of KT-621, Oral STAT6 Degrader, For Treatment Of Moderate To Severe Atopic Dermatitis
  Thu, Jun 25, 2026 7:04 AM

Financial data not available